ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
World Health Organization, 2015. Leishmaniasis: Situation and Trends and Leishmaniasis Resources. Available at: http://www.who.int/neglected_diseases/diseases/en/, http://www.who.int/gho/neglected_diseases/leishmaniasis/en/, and http://www.who.int/leishmaniasis/resources/AFGHANISTAN.pdf. Accessed October 15, 2015.
-
2.
Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S, 2007. Cutaneous leishmaniasis. Lancet Infect Dis 7: 581–596.
-
3.
Crogan J, Gunasekera H, Wood N, Sheikh M, Isaacs D, 2010. Management of Old World cutaneous leishmaniasis in refugee children. Pediatr Infect Dis J 29: 357–359.
-
4.
Piscopo TV, Mallia AC, 2006. Leishmaniasis. Postgrad Med J 82: 649–657.
-
5.
Sklavos AV, Walls T, Webber MT, Watson AB, 2010. Cutaneous leishmaniasis in a child treated with oral fluconazole. Australas J Dermatol 51: 195–197.
-
6.
Toubiana J, Armengaud JB, Dupouy Camet J, Gendrel D, 2006. Oral fluconazole treatment for extensive cutaneous leishmaniasis in an 11-year-old child. Pediatr Infect Dis J 25: 1083–1084.
-
7.
Baron S, Laube S, Raafat F, Moss C, 2004. Cutaneous leishmaniasis in a Kosovan child treated with oral fluconazole. Clin Exp Dermatol 29: 546–547.
-
8.
Aerts O, Duchateau N, Willemse P, Lambert J, 2015. Cutaneous leishmaniasis: treatment with low-dose oral fluconazole with an excellent cosmetic result. Pediatr Dermatol 32: 154–155.
-
9.
Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH, 2002. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 346: 891–895.
-
10.
Emad M, Hayati F, Fallahzadeh MK, Namazi MR, 2011. Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous Leishmania major infection: a randomized clinical trial. J Am Acad Dermatol 64: 606–608.
-
11.
Solomon M, Schwartz E, Pavlotsky F, Sakka N, Barzilai A, Greenberger S, 2014. Leishmania tropica in children: a retrospective study. J Am Acad Dermatol 71: 271–277.
-
12.
Ben Salah A, Ben Messaoud N, Guedri E, Zaatour A, Ben Alaya N, Bettaieb J, Gharbi A, Belhadj Hamida N, Boukthir A, Chlif S, Abdelhamid K, El Ahmadi Z, Louzir H, Mokni M, Morizot G, Buffet P, Smith PL, Kopydlowski KM, Kreishman-Deitrick M, Smith KS, Nielsen CJ, Ullman DR, Norwood JA, Thorne GD, McCarthy WF, Adams RC, Rice RM, Tang D, Berman J, Ransom J, Magill AJ, Grogl M, 2013. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med 368: 524–532.
-
13.
Neal RA, Allen S, McCoy N, Olliaro P, Croft SL, 1995. The sensitivity of Leishmania species to aminosidine. J Antimicrob Chemother 35: 577–584.
-
14.
Kim DH, Chung HJ, Bleys J, Ghohestani RF, 2009. Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. PLoS Negl Trop Dis 3: e381.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 318 | 238 | 12 |
| Full Text Views | 290 | 6 | 0 |
| PDF Downloads | 97 | 10 | 0 |
Successful Treatment of Cutaneous Leishmaniasis with Topical Paramomycin in a Child After Treatment Failure with Systemic Fluconazole
Anila Chacko
Anila Chacko
Division of Infectious Diseases, Hospital for Sick Children, Toronto, Canada.
Search for other papers by Anila Chacko in
Current site
Google Scholar
PubMed
Search for other papers by Anila Chacko in
Current site
Google Scholar
PubMed
Marissa Joseph
Marissa Joseph
Department of Pediatrics, University of Toronto, Toronto, Canada.
Division of Dermatology, Women's College Hospital, University of Toronto, Toronto, Canada.
Search for other papers by Marissa Joseph in
Current site
Google Scholar
PubMed
Search for other papers by Marissa Joseph in
Current site
Google Scholar
PubMed
Timothy Feltis
Timothy Feltis
Lifelabs Medical Laboratory Services, Toronto, Canada.
Search for other papers by Timothy Feltis in
Current site
Google Scholar
PubMed
Search for other papers by Timothy Feltis in
Current site
Google Scholar
PubMed
Shaun K. Morris
Shaun K. Morris
Division of Infectious Diseases, Hospital for Sick Children, Toronto, Canada.
Department of Pediatrics, University of Toronto, Toronto, Canada.
Centre for Global Child Health, Peter Gilgan Centre for Research and Learning, Hospital for Sick Children Research Institute, Toronto, Canada.
Search for other papers by Shaun K. Morris in
Current site
Google Scholar
PubMed
Search for other papers by Shaun K. Morris in
Current site
Google Scholar
PubMed
It is challenging to find safe, nonscarring and noninvasive treatment of facial cutaneous leishmaniasis (CL) in children. Herein, we report a child with CL from a region endemic for Leishmania tropica, whose lesion persisted after treatment with oral fluconazole but responded to topical paromomycin. Paromomycin should be considered early for treatment of Old World CL and is a well-tolerated and effective mode of therapy for facial lesions.
Author Notes
Authors' addresses: Anila Chacko, Division of Infectious Diseases, Hospital for Sick Children, Toronto, Canada, E-mail: anilachacko@cmcvellore.ac.in. Marissa Joseph, Department of Pediatrics, University of Toronto, Toronto, Canada, and Division of Dermatology, Women's College Hospital, University of Toronto, Toronto, Canada, E-mail: marissa.joseph@mail.utoronto.ca. Timothy Feltis, Pathology, LifeLabs Medical Laboratory Services, Toronto, Canada, E-mail: tim.feltis@lifelabs.com. Shaun K. Morris, Division of Infectious Diseases, Hospital for Sick Children, Toronto, Canada, and Centre for Global Child Health, Peter Gilgan Centre for Research and Learning, Hospital for Sick Children Research Institute, Toronto, Canada, E-mail: shaun.morris@sickkids.ca.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
World Health Organization, 2015. Leishmaniasis: Situation and Trends and Leishmaniasis Resources. Available at: http://www.who.int/neglected_diseases/diseases/en/, http://www.who.int/gho/neglected_diseases/leishmaniasis/en/, and http://www.who.int/leishmaniasis/resources/AFGHANISTAN.pdf. Accessed October 15, 2015.
-
2.
Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S, 2007. Cutaneous leishmaniasis. Lancet Infect Dis 7: 581–596.
-
3.
Crogan J, Gunasekera H, Wood N, Sheikh M, Isaacs D, 2010. Management of Old World cutaneous leishmaniasis in refugee children. Pediatr Infect Dis J 29: 357–359.
-
4.
Piscopo TV, Mallia AC, 2006. Leishmaniasis. Postgrad Med J 82: 649–657.
-
5.
Sklavos AV, Walls T, Webber MT, Watson AB, 2010. Cutaneous leishmaniasis in a child treated with oral fluconazole. Australas J Dermatol 51: 195–197.
-
6.
Toubiana J, Armengaud JB, Dupouy Camet J, Gendrel D, 2006. Oral fluconazole treatment for extensive cutaneous leishmaniasis in an 11-year-old child. Pediatr Infect Dis J 25: 1083–1084.
-
7.
Baron S, Laube S, Raafat F, Moss C, 2004. Cutaneous leishmaniasis in a Kosovan child treated with oral fluconazole. Clin Exp Dermatol 29: 546–547.
-
8.
Aerts O, Duchateau N, Willemse P, Lambert J, 2015. Cutaneous leishmaniasis: treatment with low-dose oral fluconazole with an excellent cosmetic result. Pediatr Dermatol 32: 154–155.
-
9.
Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH, 2002. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 346: 891–895.
-
10.
Emad M, Hayati F, Fallahzadeh MK, Namazi MR, 2011. Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous Leishmania major infection: a randomized clinical trial. J Am Acad Dermatol 64: 606–608.
-
11.
Solomon M, Schwartz E, Pavlotsky F, Sakka N, Barzilai A, Greenberger S, 2014. Leishmania tropica in children: a retrospective study. J Am Acad Dermatol 71: 271–277.
-
12.
Ben Salah A, Ben Messaoud N, Guedri E, Zaatour A, Ben Alaya N, Bettaieb J, Gharbi A, Belhadj Hamida N, Boukthir A, Chlif S, Abdelhamid K, El Ahmadi Z, Louzir H, Mokni M, Morizot G, Buffet P, Smith PL, Kopydlowski KM, Kreishman-Deitrick M, Smith KS, Nielsen CJ, Ullman DR, Norwood JA, Thorne GD, McCarthy WF, Adams RC, Rice RM, Tang D, Berman J, Ransom J, Magill AJ, Grogl M, 2013. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med 368: 524–532.
-
13.
Neal RA, Allen S, McCoy N, Olliaro P, Croft SL, 1995. The sensitivity of Leishmania species to aminosidine. J Antimicrob Chemother 35: 577–584.
-
14.
Kim DH, Chung HJ, Bleys J, Ghohestani RF, 2009. Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. PLoS Negl Trop Dis 3: e381.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 318 | 238 | 12 |
| Full Text Views | 290 | 6 | 0 |
| PDF Downloads | 97 | 10 | 0 |